U.S. government procurement concentration
The USG is the largest customer, so contract timing or funding changes can materially affect revenue.
- Scope
- Anthrax and smallpox MCM products
- Materiality
- high
Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a U.S.-based life sciences company built around preparedness for public health threats, with products for opioid overdose, anthrax, smallpox and other emergency-response needs. It also operates a CDMO/Bioservices platform that provides development, manufacturing, fill-finish and packaging services to external biopharma, government and NGO customers.
26,4 %
56,1 %
7,1 %
−28,8 %
5.01
2.41
| % | |
|---|---|
| Commercial Products | 30% Naloxone products sold through retail, prescription and public-health channels. |
| Anthrax MCM Products | 35% Anthrax countermeasure products procured mainly for government stockpiles and preparedness. |
| Smallpox MCM Products | 15% Smallpox preparedness products sold under government procurement programs. |
| Bioservices | 15% CDMO services including development, manufacturing, fill-finish and packaging for third parties. |
| Other Products and R&D Funding | 5% Other legacy products, procured candidates and non-dilutive contract/grant funding. |
The company sells to the U.S. government, foreign governments, and quasi-government/public-health organizations for...
- U.S. government procurementprimary
Buys anthrax, smallpox and other countermeasures for the Strategic National Stockpile and preparedness programs.
- Commercial naloxone channelsprimary
Retail pharmacies, physician-directed prescriptions and public-health buyers purchase NARCAN and KLOXXADO to address opioid overdose emergencies.
- International government and quasi-government buyerssecondary
Foreign public-sector customers procure medical countermeasures for national preparedness and response needs.
- Biopharma and biotech CDMO customerssecondary
External developers buy development, drug substance, fill-finish and packaging services to move molecules toward commercialization.
- NGOs and public-health organizationsemerging
Purchase or fund bioservices and R&D work tied to infectious disease and emergency-response programs.
Emergent is headquartered in the United States and derives most of its business from U.S. government and U.S...
- •Headquartered in the United States
- •Largest customer is the U.S. government
- •Commercial naloxone sold mainly in U.S. retail and public-health channels
- •Development and manufacturing sites in the U.S. and Canada
- •International government sales add some non-U.S. exposure
The company is focused on maintaining a portfolio of preparedness products while preserving its role as a supplier to...
01
Secure follow-on government procurement contractsshort-term
A large share of revenue depends on U.S. government stockpile and preparedness buying.
02
Grow naloxone commercial penetrationmedium-term
Commercial products diversify the business beyond government procurement cycles.
03
Monetize bioservices capacitymedium-term
CDMO services can improve utilization of specialized manufacturing assets and broaden the customer base.
04
Focus R&D on highest-value programsmedium-term
Capital is limited and the company has deprioritized some candidates, so portfolio selection is critical.
The business is exposed to procurement concentration, especially dependence on U.S. government contracts and funding...
Contract renewal and funding risk
Existing procurement contracts may not be followed by new awards when they expire.
- Scope
- Government MCM portfolio
- Materiality
- high
Manufacturing quality and compliance
Biologics and countermeasure production requires strict controls; failures can trigger recalls, delays or lost contracts.
- Scope
- All manufacturing sites and CDMO services
- Materiality
- high
Facility disruption
Unplanned outages at development or manufacturing sites can interrupt product supply and bioservices delivery.
- Scope
- U.S. and Canada sites
- Materiality
- medium
Clinical and development uncertainty
Product candidates may fail to prove safe, effective or commercially viable.
- Scope
- Pipeline programs
- Materiality
- medium
Revenue recognition timing
Affects reported sales volatility and comparability
Contract and grant accounting
Affects revenue mix and gross margin
Lease accounting
Affects balance sheet liabilities and operating expense presentation
Purchase commitments
Affects liquidity and cost structure
Impairment and divestiture accounting
Affects reported earnings and asset base
: 28.4.2026